AN ACT TO BE KNOWN AS THE "JILL GARY EURE ACT" OR "JILL'S LAW"; TO REQUIRE EACH HEALTH BENEFIT PLAN, CONTRACT OR AGREEMENT THAT IS ENTERED INTO OR RENEWED ON OR AFTER JULY 1, 2026, INCLUDING THE MEDICAID PROGRAM AND THE STATE AND SCHOOL EMPLOYEES HEALTH INSURANCE PLAN, TO OFFER COVERAGE FOR BIOMARKER TESTING FOR THE PURPOSES OF DIAGNOSIS, TREATMENT, APPROPRIATE MANAGEMENT, OR ONGOING MONITORING OF AN ENROLLEE'S DISEASE OR CONDITION WHEN USE OF THE TEST IS SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE; TO AMEND SECTIONS 43-13-117 AND 83-5-907, MISSISSIPPI CODE OF 1972, TO CONFORM TO THE PROVISIONS OF THIS ACT; AND FOR RELATED PURPOSES.
Impact
The enactment of HB 565 is set to alter existing health insurance policies significantly, making it necessary for health benefit plans to incorporate biomarker testing into their offerings. This legislation is likely to improve patient outcomes by providing healthcare professionals with essential information to guide treatment choices. Additionally, it aims to align Mississippi's health insurance coverage with nationally recognized clinical practice guidelines, potentially enhancing the standard of care available to patients within the state.
Summary
House Bill 565, known as the 'Jill Gary Eure Act' or 'Jill's Law', mandates that all health benefit plans issued or renewed on or after July 1, 2026, including the Medicaid program, must cover biomarker testing. This testing is intended for diagnosis, treatment, management, and monitoring of diseases or conditions when supported by scientific and medical evidence. Coverage will be required regardless of whether such biomarker testing includes gene mutations, protein expression, or any other related analyses that provide insights into patient health.
Sentiment
The sentiment surrounding HB 565 has been largely positive among healthcare professionals and patient advocacy groups, viewing it as a progressive step towards personalized medicine. However, some skepticism remains regarding the enforcement and implementation aspects, with concerns about how insurers will respond to this mandate and ensure adherence to the new regulations. Stakeholders in the insurance industry may express apprehension about the cost implications of expanded coverage requirements.
Contention
Notable points of contention regarding HB 565 involve the logistics of coverage and the interpretation of 'medical and scientific evidence'. Critics may argue about the potential for bureaucratic hurdles in determining which tests qualify for coverage, raising issues about accessibility for patients. Additionally, the bill amends existing laws to conform to its provisions, which could be a source of debate among lawmakers about the balance between regulatory compliance and patient-centered care.